Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA; Department of Health Behavior, Society, and Policy, Rutgers University School of Public Heath, Piscataway, New Jersey, USA.
Department of Internal Medicine, University of California, Davis, Sacramento, California, USA; Center for Healthcare Policy and Research, University of California, Davis, Sacramento, California, USA; UC Davis Comprehensive Cancer Center, University of California, Davis, Sacramento, California, USA.
J Pain Symptom Manage. 2019 Aug;58(2):208-215.e1. doi: 10.1016/j.jpainsymman.2019.04.014. Epub 2019 Apr 18.
Although patient and physician characteristics are thought to be predictive of discretionary interventions at the end of life (EoL), few studies have data on both parties.
To test the hypothesis that patient preferences and physician attitudes are both independently associated with discretionary interventions at the EoL.
We report secondary analyses of data collected prospectively from physicians (n = 38) and patients with advanced cancer (n = 265) in the Values and Options in Cancer Care study. Predictor variables were patient attitudes toward EoL care and physician-reported comfort with medical paternalism, assessed indirectly using a modified version of the Control Preference Scale. We explored whether the magnitude of the physician variable was influenced by the inclusion of particular patient treatment-preference variables (i.e., effect modification). Outcomes were a chemotherapy use score (≤14 days before death [scored 2], 15-31 days before death [scored 1], and >31 days [scored 0]) and an emergency department visit/inpatient admission score (two or more admissions in the last 31 days [scored 2], one admission [1], and 0 admissions [0]) in the last month of life.
Chemotherapy scores were nearly 0.25 points higher if patients expressed a preference for experimental treatments with unknown benefit at study entry (0.238 points, 95% CI = 0.047-0.429) or reported an unfavorable attitude toward palliative care (0.247 points, 95% CI = 0.047-0.450). A two-standard deviation difference in physician comfort with medical paternalism corresponded to standardized effects of 0.35 (95% CI = 0.03-0.66) for chemotherapy and 0.33 (95% CI = 0.04-0.61) for emergency department visits/inpatient admissions. There was no evidence of effect modification.
Patient treatment preferences and physician attitudes are independently associated with higher levels of treatment intensity before death. Greater research, clinical, and policy attention to patient treatment preferences and physician comfort with medical paternalism might lead to improvements in care of patients with advanced disease.
尽管患者和医生的特征被认为可以预测生命末期(EoL)的自由裁量干预措施,但很少有研究同时涉及双方的数据。
检验患者偏好和医生态度均与生命末期自由裁量干预措施独立相关的假设。
我们报告了从癌症护理价值观和选择研究中前瞻性收集的医生(n=38)和晚期癌症患者(n=265)的数据的二次分析。预测变量是患者对生命末期护理的态度和医生报告的对医学家长主义的舒适度,通过使用控制偏好量表的改良版间接评估。我们探讨了医生变量的幅度是否受到包括特定患者治疗偏好变量的影响(即,效应修饰)。结果是在生命的最后一个月中化疗使用评分(死亡前≤14 天[评分为 2],15-31 天[评分为 1],>31 天[评分为 0])和急诊就诊/住院评分(最后 31 天内两次或更多次就诊[评分为 2],一次就诊[评分为 1],无就诊[评分为 0])。
如果患者在研究入组时表达了对具有未知益处的实验性治疗的偏好(0.238 分,95%CI=0.047-0.429)或对姑息治疗持不利态度(0.247 分,95%CI=0.047-0.450),则化疗评分高出近 0.25 分。医生对医学家长主义的舒适度差异两个标准差对应于化疗的标准化效应为 0.35(95%CI=0.03-0.66)和急诊就诊/住院的标准化效应为 0.33(95%CI=0.04-0.61)。没有证据表明存在效应修饰。
患者的治疗偏好和医生的态度与死亡前更高水平的治疗强度独立相关。更多的研究、临床和政策关注患者的治疗偏好和医生对医学家长主义的舒适度,可能会改善晚期疾病患者的护理。